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Abrogation of collagen-induced 
arthritis by a peptidyl arginine 
deiminase inhibitor is associated 
with modulation of T cell-mediated 
immune responses
Joanna Kawalkowska1,*, Anne-Marie Quirke1,*, Fatemeh Ghari2, Simon Davis3, 
Venkataraman Subramanian4, Paul R. Thompson4, Richard O. Williams1, Roman Fischer3, 
Nicholas B. La Thangue2 & Patrick J. Venables1
Proteins containing citrulline, a post-translational modification of arginine, are generated by peptidyl 
arginine deiminases (PAD). Citrullinated proteins have pro-inflammatory effects in both innate and 
adaptive immune responses. Here, we examine the therapeutic effects in collagen-induced arthritis 
of the second generation PAD inhibitor, BB-Cl-amidine. Treatment after disease onset resulted in 
the reversal of clinical and histological changes of arthritis, associated with a marked reduction in 
citrullinated proteins in lymph nodes. There was little overall change in antibodies to collagen or 
antibodies to citrullinated peptides, but a shift from pro-inflammatory Th1 and Th17-type responses 
to pro-resolution Th2-type responses was demonstrated by serum cytokines and antibody subtypes. 
In lymph node cells from the arthritic mice treated with BB-Cl-amidine, there was a decrease in 
total cell numbers but an increase in the proportion of Th2 cells. BB-Cl-amidine had a pro-apoptotic 
effect on all Th subsets in vitro with Th17 cells appearing to be the most sensitive. We suggest that 
these immunoregulatory effects of PAD inhibition in CIA are complex, but primarily mediated by 
transcriptional regulation. We suggest that targeting PADs is a promising strategy for the treatment of 
chronic inflammatory disease.
Citrullination is a post-translational modification (PTM) of arginine, catalysed by peptidyl arginine deiminases 
(PADs) and may be important in generating autoantibodies to citrullinated proteins in rheumatoid arthri-
tis (RA). Citrullination can also be pathogenic by modulating transcription of cytokines and generation of 
pro-inflammatory extracellular proteins (reviewed in Wegner et al.1). There are 5 different PAD enzymes, with 
PAD2 and PAD4 being the main isoforms involved in arthritis1. Traditionally PAD4 was thought to be the more 
important, as a polymorphism of the PADI4 gene is associated with the prevalence of RA, but mainly in Asian 
populations2. Furthermore, PAD4 was thought to be the only PAD which could localize to the nucleus and, 
therefore, be involved in transcriptional regulation2,3. However more recent studies have highlighted the relative 
importance of PAD2 by showing it to be up-regulated in the inflamed joint4 and by demonstrating that like PAD4, 
it could translocate to the nucleus and have a specific role in the citrullination of histone H35.
To examine the potential for PAD inhibition in the treatment of inflammatory disease, we chose 
collagen-induced arthritis (CIA) as a robust and reproducible model of RA6. We used the second generation 
pan PAD inhibitor BB-Cl-amidine (BB-Cl) which is equipotent against PAD4 as its precursor drug, Cl-amidine, 
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but 10 times more potent against PAD27. BB-Cl-amidine retains the critical elements of Cl-amidine but has a 
C-terminal benzimidazole and N-terminal biphenyl moiety (the “BB” in its nomenclature), which increases its 
plasma half-life and facilitates cellular uptake. In previous studies, the PAD inhibitor Cl-amidine was shown to 
have a modest anti-inflammatory effect, when given prophylactically at high doses8. In the current study, we use 
a therapeutic, rather than prophylactic, treatment protocol, which is more relevant for translation into human 
disease.
Here we demonstrate that BB-Cl-amidine reverses immune-mediated joint inflammation in a pre-clinical 
mouse model of arthritis. By targeting PAD enzymes, BB-CL-amidine reduces citrullination which is induced 
during inflammatory conditions such as arthritis. In addition, BB-CL-amidine-treatment decreases Th1 and 
Th17 responses in vivo while conversely, Th2 responses are supported. Thus, we report a novel treatment for 
immune-mediated pathologies in which the balance between Th17 and Th2 cells is disturbed.
Results
BB-Cl-amidine reduces inflammation and joint destruction in arthritic mice. To examine the 
therapeutic potential of BB-Cl-amidine in vivo we used the drug in a treatment protocol, that is, after the onset 
of arthritis. Compared with vehicle-treated mice, there was reduced clinical scoring (P < 0.0001 from 5 days 
treatment), paw swelling (P < 0.0001 from 6 days treatment), with a partial response in all measures at 1 mg/kg 
(Fig. 1a,b).
These clinical changes were reflected in a significant reduction of the histology scores (Fig. 1c). The histolog-
ical changes in the vehicle treated group were typical of that seen in severe CIA (intense inflammatory cell infil-
tration and severe erosive changes) and almost completely normalised in the 10 mg/kg treatment group (Fig. 1d). 
During the 9 days of treatment, BB-Cl-amidine did not induce any adverse effects in the arthritic mice such as 
excessive weight loss (data not shown).
BB-Cl-amidine reduces protein citrullination in vivo without affecting the ACPA response. To 
confirm that treatment with BB-Cl-amidine reduced protein citrullination in vivo, we compared inguinal lymph 
nodes from arthritic mice treated with BB-Cl-amidine with vehicle-treated controls using mass spectrometry. 
We chose lymph nodes for study, as opposed to joints, because of our interest in the possible immunoregulatory 
Figure 1. BB-Cl-amidine ameliorates severity of CIA. The severity of disease was evaluated daily by  
(a) clinical score and (b) paw swelling of the first hind paw to develop arthritis. Pooled data of the mean and 
SEM from two independent CIA experiments are shown (n = 12–13 animals per group). *P < 0.05; **P < 0.01; 
****P < 0.0001. Two-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test. (c) Mean 
histological scores (n = 4–5 per group). Error bars represent ± SEM (*P < 0.05). One-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparisons test relative to vehicle-treated mice. (d) Representative images 
of the metatarsal-phalangeal joint of a vehicle or BB-Cl-amidine 10 mg/kg/day treated mouse are shown. In the 
vehicle-treated mice, there was a marked inflammatory infiltrate, bone erosion (arrows), destruction of articular 
cartilage (*), and proliferation of synovial membrane (sm). In the 10 mg/kg BB-Cl-amidine treated mice the 
cartilage (*) and joint space (js) were preserved, but there were still minor proliferative changes in the synovial 
membrane (sm).
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effects of citrullination. No citrulline residues were detected in lymph nodes from naïve mice whereas the fre-
quency of detected citrulline residues was increased in the vehicle-treated mice with arthritis. The frequency 
of detected citrulline residues was reduced by approximately 90% in the 10 mg/kg group with no change in 
the 1 mg/kg group (Fig. 2a). The detected citrulline residues were confirmed in every case by visual exami-
nation of the spectra. Individual citrullinated residues were detected in 34 different proteins (Supplementary 
Table 1). Noteworthy amongst these was R93 from histone H4, and R117 from histone H3.2. To examine the 
anti-citrullinated protein antibody (ACPA) response in the mice, we chose two well-characterised peptides from 
citrullinated alpha-enolase (CEP-1) and from citrullinated vimentin (cVim), on the basis that both sequences 
were highly conserved between mice and humans, both had arginine-containing controls, and both had been 
previously demonstrated to give robust and reproducible results in murine systems9,10. Both anti-CEP-1 and 
anti-cVim was increased in the collagen immunised mice, but in neither case was the response citrulline-specific, 
as illustrated by binding to the control peptides (REP-1 and Vim) (Fig. 2b,c). This confirmed a lack of a true ACPA 
response in CIA mice, which was not affected by BB-Cl-amidine treatment.
BB-Cl-amidine treatment of arthritic mice is associated with Th2-type responses. Having 
demonstrated that the profound therapeutic benefit of BB-Cl-amidine in CIA was unlikely to be due to modula-
tion of an ACPA response, we then went on to examine other possible immunological mechanisms. The level of 
anti-bovine type II collagen IgG1 was significantly increased in the mice treated with BB-Cl-amidine at 10 mg/kg. 
There was also a marginal increase in IgG2a anti-collagen antibodies but an overall fall in the ratio of the IgG2a/
IgG1 in proportion to the dose of BB-Cl-amidine, indicating the possibility of a switch to Th2-type response 
induced by the drug (Fig. 3a). This was confirmed by the fact that serum levels of the Th2-type cytokines, IL-4, 
IL-5 and IL-10, were raised in response to treatment with BB-Cl-amidine, with IL-5 and IL-10 levels reaching sta-
tistical significance in the higher treatment dose (Fig. 3b). Levels of IL-6, TNF-α , IFN-γ , IL-1β , IL-2 and IL-17A 
were unchanged (Fig. 3c and data not shown).
BB-Cl-amidine modulates the CD4+ T cell cytokine expression in arthritic mice and their prolif-
erative capacity ex vivo. To examine responses of T cells more directly, we examined T cells ex vivo taken 
Figure 2. BB-Cl-amidine targets protein citrullination in vivo with little effect on immune responses 
against citrullinated antigens. (a) BB-Cl-amidine treatment of arthritic mice lead to a significant decline in 
the level of global protein citrullination in the lymph nodes as detected by mass spectrometry (n = 5–6 animals 
per group). *P < 0.05; **P < 0.01. Citrulline frequency is calculated as percentage of validated and citrullinated 
peptide sequences/identified peptides sequences at 1% false discovery rate. Error bars represent ± SEM. 
One-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test relative to vehicle-treated 
animals (control). (b,c) There were no differences between treatment groups in IgG immune responses against 
citrullinated α -enolase (CEP-1) and vimentin (cVim) versus their arginine-bearing controls. Each data point 
represents one animal. OD, optical density.
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from inguinal lymph nodes at day 10 after disease onset from each of the groups of arthritic mice. Compared to 
naive mice, there was an increase in numbers of total cells and CD4+ T cells in the vehicle treated group, which fell 
in response to BB-Cl-amidine treatment (Fig. 4a,b). There was a marked increase in the proliferative response of 
lymph node T cells to anti-CD3 stimulation in the vehicle-treated mice with CIA (Fig. 4c), which was significantly 
reduced in T cells taken from mice treated with the higher dose of BB-Cl-amidine, indicating an immunoregula-
tory or immunosuppressive effect of the drug.
To dissect the mechanisms of BB-Cl-amidine further, we then quantified T helper cell subsets in the lymph 
nodes of arthritic mice on day 10. There was a fall in the total number of pro-inflammatory Th1 cells, but no 
change in the percentage of cells producing IFN-γ (Fig. 5a). In contrast, there was a rise in the percentage of Th2 
cells (CD4 and IL-4 positive), reaching statistical significance at the 10 mg/kg dose of BB-Cl-amidine (Fig. 5b). 
These findings confirm and consolidate the increase Th2/Th1 ratio inferred by our findings with the IgG sub-
classes and cytokine profiles (Fig. 3). In our study, we found a marked suppression of Th17 cells by BB-Cl-amidine 
ex-vivo expressed both as total cell numbers and as percentages of CD4 T cells (Fig. 5c). In the mice with CIA 
there was an increase in Treg numbers compared to naïve animals, but importantly no effect from treatment with 
BB-Cl-amidine at either dose (Fig. 5d).
BB-Cl-amidine has a direct effect on cytokine secretion and survival of CD4+ T helper sub-
sets. To determine whether the suppression of T helper responses was a direct effect of BB-Cl-amidine, we 
cultured naive CD4+ T cells from healthy, unimmunised mice under Th1, Th17 or Th2 promoting conditions 
Figure 3. Analysis of IgG subclass anti-collagen antibodies and serum cytokines indicates an induction of 
a Th2 response by treatment with BB-Cl-amidine. (a–c) Pooled data from 2–3 independent CIA experiments 
are shown (n = 12–22 animals per group). (a) There was a significant rise in IgG1 anti–bovine collagen type II 
(bCII) antibodies in the 10 mg/kg BB-Cl-amidine treated group, with relatively little change in IgG2a anti-bCII. 
There was a fall in the IgG2a/IgG1 ratio with increasing BB-Cl-amidine treatment indicating induction of a Th2 
response. AU, arbitrary units. (b) Increased serum levels of the Th2 cytokines IL-5 and IL-10. (c) There was no 
change in the pro-inflammatory cytokines IL-6, interferon-γ and TNF-α . (b,c) Each data point represents one 
animal. (a–c) Error bars represent ± SEM. One-way analysis of variance (ANOVA) with Dunnett’s multiple 
comparisons test relative to vehicle-treated animals. *P < 0.05; ***P < 0.001; ****P < 0.0001; ns, not significant.
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5Scientific RepoRts | 6:26430 | DOI: 10.1038/srep26430
for 5 days with BB-Cl-amidine or vehicle added at the start of the culture. BB-Cl-amidine at 10 μ M inhibited the 
induction of Th1, Th17 cells and in contrast to the ex-vivo findings, also Th2 cell induction (Fig. 6a–c). Similarly, 
analysis of day 5 culture supernatants revealed that BB-Cl-amidine at 10 μ M suppressed IFN-γ and IL-17A secre-
tion. Interleukin-4 levels were apparently unchanged, but this could be explained by the addition of extrinsic IL-4 
to the cultures as part of the Th2 induction protocol (data not shown). However when IL-5 levels were measured 
as an independent Th2 cytokine, levels fell to the same extent as seen with IFN-γ and IL-17A (Fig. 6c). In addi-
tion, the number of total cells in Th1 conditions was reduced after co-culture with BB-Cl-amidine for 5 days, 
suggesting that citrullination is an important factor in the proliferation and survival of at least some T helper cell 
populations (Fig. 6d).
As BB-Cl-amidine inhibited the induction of Th subsets, we addressed the question of whether already dif-
ferentiated Th cells, such as those present at the site of inflammation would also be susceptible to BB-Cl-amidine 
treatment. After differentiating CD4+ T cells under Th1, Th17 and Th2 conditions for 5 days, BB-Cl-amidine 
or vehicle were added for 20 hours. As in the previous experiment in which the drug was added at the start of 
the culture, there was marked suppression of Th1, Th17 and Th2 cells (Fig. 7) suggesting that Th subsets were 
still susceptible to the drug even after they had been induced and differentiated. When we examined whether 
BB-CL-amidine affected T cell survival by inducing apoptosis we found that BB-CL-amidine at 10 μ M (high dose) 
significantly affected cell survival in all culture conditions, with a trend towards increased sensitivity of Th17 cells 
to PAD inhibition.
Discussion
In this study, we have shown that the second generation PAD inhibitor, BB-Cl-amidine, reversed joint inflamma-
tion both clinically and histologically in collagen-induced arthritis at a dose of 10 mg/kg, with a partial response 
at 1 mg/kg. Mass spectrometry of proteins identified in lymph nodes, indicate effective inhibition of citrullination 
in vivo, and analysis of serological responses and cytokine production suggested that the profound therapeutic 
response to the drug was unrelated to the ACPA response, but associated with suppression of pro-inflammatory 
Th1 and Th17 responses with a relative increase in Th2 responses in vivo and ex-vivo. In vitro experiments indi-
cated that this was a direct effect of the drug on T helper cells, though, under these conditions all phenotypes were 
inhibited, including Th2, Th17 and Th1 cells.
The almost complete reversal of arthritis in our study is in contrast to the modest effects seen with the first 
generation PAD inhibitor, Cl-amidine, reported by Willis et al.8. They administered Cl-amidine at similar daily 
doses (1 mg/kg and 10 mg/kg), with an additional group treated with 50 mg/kg. Unlike our study, they used a 
prophylactic regimen in which treatment was started immediately after immunisation and continued to day 35, so 
that at a given dose, each mouse received nearly 4 times as much Cl-amidine compared with the BB-Cl-amidine 
used in our study. In spite of this much more aggressive treatment regime, the reduction of arthritis was in the 
region of 50%, and with an approximately 30% improvement in histology scores. Cl-amidine has also been used 
in mouse models of lupus7, inflammatory bowel disease11 and cardiovascular disease12, with similar profiles of 
partial therapeutic responses.
The available data involving Cl-amidine suggest that most of its therapeutic effect is due to inhibition of 
PAD4. In the study from Willis et al.8 the dose response to Cl-amidine plateaued at 10 mg/kg/day with no further 
improvement with 50 mg/kg. Furthermore, in unpublished work available on line13 Willis showed that GSK283, a 
PAD4-specific inhibitor, gave a very similar therapeutic profile. A contribution of PAD4 to the severity of arthritis 
in other mouse models is suggested by a partial amelioration of the disease in PAD4 knockout mice in TNFα 
Figure 4. BB-Cl-amidine restrains T cell numbers and proliferation in inguinal lymph nodes from mice 
with CIA. (a–c) Data from CIA experiment is shown (n = 7 animals per group). (a) The total number of cells 
in the inguinal lymph nodes on day 10 was decreased with BB-Cl-amidine treatment. (b) The total number of 
CD4+ T cells in the inguinal lymph nodes of CIA mice is significantly lower in BB-Cl-amidine-treated mice.  
(c) BB-Cl-amidine decreases the percentage of proliferating CD4+ T cells (CD4+ BrdU+) in response to 
anti-CD3 antibody stimulation ex vivo. (a–c) Error bars represent ± SEM. One-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparisons test relative to vehicle-treated animals. *P < 0.05; **P < 0.01; 
***P < 0.001; ns, not significant.
www.nature.com/scientificreports/
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Figure 5. BB-Cl-amidine modulates the cytokine profile of T helper cell subsets, but not Tregs in the 
lymph nodes of arthritic mice. (a–d) Arthritic mice were culled on day 10 and the therapeutic effect of BB-CL-
amidine on CD4+ T cells in lymph nodes was determined by flow cytometry (n = 7). BB-Cl-amidine decreases 
the frequency of (a) IFN-γ and (b) IL-17A producing cells whereas (c) IL-4 producing cells are increased. One 
representative FACS plot for each cell type is shown. Numbers in plots indicate the percent of cytokine secreting 
cells gated on live CD4+ T cells. RORγ T, retinoic acid receptor-related orphan nuclear receptor gamma. (d) BB-
Cl-amidine treatment does not alter the number of Tregs in the lymph nodes of mice with CIA. The percentage 
of CD25+ FoxP3+ cells among CD4+ T cells as well as the total number of Tregs in the lymph nodes is shown. 
One representative dot plot is shown. Numbers in plots indicate the percent of CD25+ FoxP3+ cells among 
live CD4+ T cells. (a–d) Error bars represent ± SEM. One-way analysis of variance (ANOVA) with Dunnett’s 
multiple comparisons test relative to vehicle-treated animals. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; 
ns, not significant.
www.nature.com/scientificreports/
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Figure 6. BB-Cl-amidine inhibits the induction of Th1 and Th17 cells and reduces their numbers in vitro. 
(a–d) Mouse CD4+ T cells were cultured in Th1, Th2 or Th17 differentiating conditions with BB-Cl-amidine or 
vehicle (DMSO) at 1 μ M, 2.5 μ M or 10 μ M. After 5 days cell culture supernatants were investigated for cytokines, 
the cells were counted and analysed by flow cytometry. Culturing CD4+ T cells with BB-Cl-amidine decreases 
the amount of (a) IFN-γ , (b) IL-17A and (c) IL-4. (d) Culturing CD4+ T cells with BB-Cl-amidine decreases the 
total number of cells in Th1 conditions. (a–d) Shown is pooled data from 3 independent experiments with  
3 biological repeats per experiment (n = 9 per group). Error bars represent ± SEM. One-way analysis of variance 
(ANOVA) with Dunnett’s multiple comparisons test relative to vehicle (control). *P < 0.05; **P < 0.01; ns, not 
significant.
www.nature.com/scientificreports/
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transgenic mice and in mice with glucose-6 isomerase-induced arthritis14,15. Interestingly PAD4 knockout does 
not protect against passively-transferred, antibody-mediated arthritis16.
We propose that markedly improved therapeutic response to BB-Cl-amidine in CIA is due to its improved 
pharmacokinetics and its relative potency against PAD2 compared to Cl-amidine, which was documented in 
detail by Knight et al.7. They also showed that 1 mg/kg of BB-Cl-amidine was roughly equivalent to 10 mg/kg of 
Cl-amidine in inhibiting the formation of neutrophil extracellular traps, improving endothelial dysfunction and 
inhibiting manifestations of murine lupus nephritis7. The increased activity of BB-Cl-amidine against PAD2, in 
addition to its more favourable pharmacokinetic properties, could explain its capability of abrogating arthritis 
even when treatment is started after the onset of disease. Thus, the development of selective PAD4 inhibitors17 for 
potential therapy in human disease may have been focussing on the wrong isoform of the enzyme.
Using mass spectrometry, citrulline residues were identified in 34 proteins. Noteworthy amongst these was 
R93 from histone H4, and R117 from histone H3.2. Both are novel citrullination sites on histones and of interest, 
as R93 is present at the H4/H2B interface and H3 R117 is on the surface of the nucleosomal core particle, close to 
the DNA18. Citrullination of either could result in decondensation of the nucleosome resulting in increased tran-
scription. Interestingly, R117 from histone H3.2 appeared to be citrullinated more in the vehicle-treated arthritic 
mice and contrary to expectations, citrullination of R93 from histone H4 was only detected in the BB-Cl-amidine 
treated animals. However, numbers are too small to conclude that the differences resulted from in vivo treatment. 
Future studies will have to address the question of the role of citrullination at both of these sites and their poten-
tial influence on gene transcription.
Whilst it is important to appreciate that mass spectrometry is not quantitative19, the 90% reduction in the 
number of citrullinated residues detected in the group treated with 10 mg/kg BB-Cl-amidine would suggest that 
Figure 7. BB-Cl-amidine induces apoptosis and modulates the cytokine profile of CD4+ T helper cells  
in vitro. (a–c) Mouse naïve CD4+ T cells were cultured in Th1, Th2 or Th17 differentiating conditions. Vehicle 
(DMSO) or BB-Cl-amidine were added to the last 20 hours of culture. After 5 days the cells were analysed by 
flow cytometry to detect cytokines or annexin V and propidium iodide-positive cells. Adding BB-Cl-amidine to 
cultured T helper cells decreases the amount of (a) IFN-γ , (b) IL-17A and (c) IL-4. (a–c) Shown is pooled data 
from 1–2 independent experiments with 3 biological repeats per experiment (n = 3–6 per group). Error bars 
represent ± SEM. One-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test relative to 
vehicle (control). *P < 0.05; **P < 0.01; ****P < 0.0001.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:26430 | DOI: 10.1038/srep26430
the drug does effectively deplete citrullinated proteins in vivo. To examine the ACPA response in these mice, 
we chose sequences from α -enolase and vimentin that were highly conserved between mice and humans. Both 
had arginine-containing controls, and both had been previously tested in murine systems4 (and unpublished 
our observations). Using these peptides, we demonstrated a non-citrulline-specific antibody response to both 
peptides in the collagen immunised mice compared to naive controls which in the case of vimentin was sup-
pressed by the higher treatment dose. The lack of ACPA in our mice is entirely consistent with the classic studies 
of Vossennar et al.20. They examined several mouse models of experimental arthritis and found that several, 
including CIA, had antibodies detected by first generation CCP assay based on citrullinated sequences from filag-
grin. However, when tested with the arginine control peptides, they found equal levels of antibody binding and 
concluded that this population of anti-CCP antibodies, unlike those found in human RA, where not true ACPA. 
Other studies have found citrulline-specific antibodies late in disease and these have been attributed to “epitope 
spreading”. However, these ACPA are at very low levels, compared to the anti-collagen response, and, in general, 
have only been cited as possibly having an amplifying effect8 rather than being the primary mechanism of joint 
destruction in CIA. In our mice, the experiment was terminated after only 10 days after the onset of arthritis and 
the response occurred within 5–6 days of treatment. This rapid response together with our serological data would 
suggest that inhibition of citrullination of autoantigens is an unlikely mechanism for the rapid and profound 
therapeutic effect of BB-Cl-amidine.
Our study suggests that the response to treatment with BB-Cl-amidine is due to suppression of Th1 and Th17 
responses associated with a relative induction of a Th2 type response. Th17 cells are regarded as the most patho-
genic subset of T helper cells in chronic arthritis and were identified in this study by their co-expression of RORγ T, 
the Th17 master transcription factor, and IL-17A21,22. IL-17A increases pro-inflammatory cytokine secretion 
and recruits monocytes and neutrophils to sites of inflammation23–25 and plays a significant pathogenic role in 
CIA21,26–28. This indicates that treatment with BB-Cl-amidine is not simply immunosuppressive but immunoreg-
ulatory because it also favoured the anti-inflammatory effect of Th2 cells. However, lymph nodes contain factors 
other than T cells which could be modulated by PAD inhibition. These include monocytes and stromal proteins 
which could themselves affect the activity of T cells. Therefore, to confirm that the effect of BB-Cl-amidine on T 
helper subset was direct, we went on to demonstrate that BB-Cl-amidine incubated with Th17 cells induced from 
naïve (unimmunised mice) suppressed IL-17A production in a dose-dependent manner. There was a similar but 
less marked effect on IFN-γ production by Th1 cells, and IL-5 production by Th2 cells. This, in turn, suggests that 
the therapeutic effect of BB-Cl-amidine is predominantly at the transcriptional level though selectivity for the 
different T helper subtypes seen in vivo was less well demonstrated in vitro. However analysis of the subtype cell 
numbers and the number of apoptotic cells suggest that Th17 cells are more sensitive to PAD inhibition than other 
T helper cell types. Much of the selective effects on Th2 subsets observed in vivo, could well be indirect, perhaps 
due to changes in antigen presenting cells. These cell types are known to be rich in PAD2 and PAD429,30 and are 
also capable of directing T helper subsets. Antigen presenting cells are abundant in lymph nodes in vivo, but they 
were not present in our T helper cell cultures in vitro.
Our data suggest that pan-PAD inhibitors could become a new class of targeted small molecular weight com-
pounds with a potential role in the treatment of a variety of IL-17A driven diseases. These include the spondy-
loarthropathies and inflammatory bowel disease which are known to respond to anti-IL-17 antibody treatment31. 
PAD inhibition may have an additional benefit in treating humans with RA, a disease driven by pathogenic 
autoantibodies to citrullinated proteins. Therefore in RA, PAD inhibition could not only suppress disease by 
its immunoregulatory effects, but also by inhibiting the formation of the citrullinated proteins that drive the 
autoantibody response. There is currently great interest in the therapeutic effect of the induction Tregs by toler-
izing protocols32–34 and the administration of GM-CSF35,36 in mice with CIA. In our study Tregs were unaffected 
by BB-Cl-amidine. Therefore, we would predict that combination treatment aimed to induce Tregs along with 
PAD inhibition might be synergistic in the treatment of RA whilst also minimising potential toxicity. Whichever 
approach is taken, we now propose that PAD inhibition, alone, or in combination with other drugs, is a promising 
approach to treating chronic inflammatory disease in humans.
Methods
Induction and assessment of arthritis. All animal experiments were approved by the Clinical Medicine 
Animal Welfare Ethical Review Board and the UK Home Office and conducted in accordance with the approved 
guidelines. Arthritis was induced in DBA/1 mice as described previously6. Ten to 12-week-old male DBA/1 mice 
(Harlan) received one subcutaneous 100 μ L injection of 200 μ g bovine type II collagen in complete Freund’s adju-
vant (BD Biosciences) at the base of the tail and on the flank. Post-immunization the mice were monitored daily 
and once an animal showed signs of arthritis it was randomly assigned to a treatment group. Disease severity 
was assessed daily by an experienced investigator. Arthritis severity was scored as follows: 0 = normal, 1 = slight 
swelling and/or erythema, 2 = pronounced swelling, 3 = ankylosis. All four limbs were scored, giving a maximum 
possible score of 12 per animal. Hind paw swelling was measured daily with calipers (Krœplin).
BB-Cl-amidine. BB-Cl-amidine was synthesised as described7 and given as daily intraperitoneal doses of 
1 mg/kg or 10 mg/kg or vehicle (5% DMSO, 10% cyclodextran in H20). All procedures were approved by the 
Clinical Medicine Animal Welfare Ethical Review Board and the UK Home Office.
Histological analysis of arthritic paws. Hind paws of animals with CIA on day 10 were fixed in par-
aformaldehyde, decalcified with EDTA, and paraffin-embedded sections were stained with haematoxylin and 
eosin. Each joint was scored as follows: 0 = normal; 1 = cell infiltration with no signs of joint erosion; 2 = inflam-
mation with the presence or erosions limited to discrete foci; and 3 = severe and extensive joint erosion with loss 
of architecture. Three hind paw joints (proximal interphalangeal, metatarsal phalangeal and tarsal-metatarsal) 
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were scored and a mean calculated, giving a maximum possible score of 3 per animal. The histological scoring was 
conducted by an experienced blinded to the study investigator.
Cytokine detection. Cytokines were detected in serum using the Meso Scale Discovery platform according 
to manufacturer’s instructions.
Antibody measurements. Serum levels of bovine anti–type II collagen–specific IgG1 and IgG2a were 
measured by ELISA as previously described37,38. Pooled serum from vehicle-treated mice was used as a standard. 
To measure anti-citrullinated protein antibodies (ACPA) we used peptides from citrullinated α -enolase (CEP-1; 
amino acids 4–21: KIHA-Cit-EIFDS-Cit-GNPTVE) and citrullinated (Cit) vimentin cVim (amino acids 60–75: 
VYAT-Cit-SSAV-Cit-L-Cit-SSVP), together with arginine-containing controls for each peptide, REP-1 and Vim 
respectively9.
Analysis of T-cell responses. On day 10 after disease onset, the animals were culled and a single-cell sus-
pension prepared from inguinal lymph nodes. 2 × 105 cells per well were cultured in a 96-well plate in 200 μ L 
RPMI-1640 with L-glutamine, 10% fetal calf serum, and penicillin/streptomycin (all from Life Technologies).
For immunophenotyping, cells were stimulated with 0.02 μ g/mL PMA, 0.4 μ M ionomycin and 1.25 μ g/mL 
Brefeldin A (all from Sigma-Aldrich) for 4 hours. The antibodies used for surface and intracellular staining are 
listed in Supplementary Table 2. The gating strategy used to identify CD4+ T cell subpopulations is described in 
Supplementary Figure 1. The samples, with the exception of samples in which IL-4 was detected, were fixed and 
permeabilized with the buffers provided with the FoxP3 Staining Buffer Set (eBioscience). IL-4+ T cells were fixed 
with a 2% solution of formaldehyde (Merck) in PBS. The permeabilization buffer contained: 0.05% saponin, 0.5% 
BSA (both from Sigma-Aldrich), 2 mM EDTA (Invitrogen), 0.02% sodium azide (G-Biosciences) and PBS. Data 
was acquired on a CANTO II flow cytometer using FACSDIVA software (all BD Biosciences) and analysed using 
FlowJo software.
For measurement of proliferative responses, inguinal lymph node cells were cultured for 48 hours in 
the presence of 0.1 μ g/ml anti-CD3ε antibody (clone: 145-2C11) (eBioscience). The thymidine analog, 
5-bromo-2-deoxyuridine (BrdU, 50 μ M), was added for 18 hours to access cell proliferation. BrdU staining 
was carried out according to manufacturer’s protocols with an anti-BrdU conjugated antibody (clone B44) (BD 
Biosciences).
Mouse T helper differentiation assays. Naïve CD4+ T cells were isolated from healthy non-immunised 
BALB/c mice (The Jackson Laboratory) using a CD4+ CD62L+ T Cell Isolation Kit (Miltenyi). Naïve CD4+ T 
were cultured in Iscove’s Modified Dulbecco’s Medium with Knockout Serum Replacement (Th17) or RPMI-1640 
with 10% fetal calf serum (all from Invitrogen) for 5 days in the presence of Th1 (12 ng/mL IL-12 and 10 μ g/mL 
anti-IL-4), Th2 (40 ng/mL IL-2, 40 ng/mL IL-4 and 10 μ g/mL anti-IFN-γ ) or Th17 (3 ng/mL TGF-β , 30 ng/mL 
IL-6, 10 ng/mL IL-1β , 10 ng/mL IL-23, 10 μ g/mL anti-IL-4 and 10 μ g/mL anti-IFN-γ ) conditions and anti-mouse 
CD3 (1.0 μ g/mL; clone 145-2C11, eBioscience) and anti-mouse CD28 (0.5 μ g/mL; clone 37.51, eBioscience). 
Neutralising antibodies were supplied from BioLegend. All cytokines were supplied by PeproTech, except IL-23 
(R&D Systems).
Mass spectrometric analysis of proteins. Proteins were precipitated from cells using chloroform/metha-
nol followed by proteolysis with trypsin39. Peptides were desalted and analysed as described previously19. Data was 
analysed with PEAKS19. Spectra representing citrullinated peptides were manually inspected for mono-isotopic 
precursor and fragment annotation to exclude false positives.
Apoptosis detection. Dead and apoptotic cells were detected using the Annexin-V Apoptosis Detection Kit 
along with propidium iodide according to manufacturer’s instructions (Sigma-Aldrich).
Statistical analysis. Data are presented as the arithmetic mean ± standard error of mean (SEM). 
Comparisons between groups were carried out using an analysis of variance (ANOVA) with Dunnett’s (one-way) 
or Tukey’s (two-way) post hoc test. Probability values (P) of less than 0.05 were considered significant. For the 
animal studies (collagen-induced arthritis, CIA), > 8 mice were randomly selected per group. This was based 
on the calculation that a sample size of 8 per group would have a 90% power to detect a difference between a 
mean clinical score of 2 with a significance level (alpha) of 0.05 (two-tailed). The in vivo CIA experiments were 
repeated twice to ensure reproducibility and then the data pooled together. For the in vitro studies, experiments 
were conducted with at least 3 biological repeats. The experiments were repeated two to three times to ensure 
reproducibility and then the data pooled together. Statistical analysis was performed using GraphPad PRISM 
(Graphpad Software Inc., USA).
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